FORT COLLINS -- Innosphere client company Immunocept Medical Products met its graduation goal of achieving a successful acquisition by CytoPherx.
The acquisition with CytoPherx will ensure a synergistic approach to branding, manufacturing and customer call points, Immunocept said.
“This merger enables the immediate launch of Immunocept’s FDA-cleared blood filter, creating revenues and early brand recognition for the family of products to solve several real-world problems,” said Charles J. Fisher, Jr., CytoPherx CEO.
CytoPherx is currently in the process of rebranding as SeaStar Medical to give a fresh start to both companies.
Immunocept Medical Products is based in Denver and recently received FDA clearance to market its CLR 2.0 blood filter for use in patients with acute kidney injury, pulmonary edema, or congestive heart failure.
“Both companies coming together strengthens IP protection with the combined patent portfolios,” said Chris Jaynes, SeaStar Medical chief commercialization officer and former Immunocept CEO.
“Combined, there are 62 issued and pending U.S. patents covering nearly everything that can be done with hollow fiber membranes in the acute inflammation and multi-organ failure therapeutic space.
“Our technologies greatly improve efficiencies and lower costs of manufacturing.”
The acquisition further strengthens the CytoPherx technology, known as the Selective Cytopheric Device (SCD), developed to treat very ill patients with acute kidney injury and multiple organ failures.
Both the Immunocept and the CytoPherx blood filters are designed to fit onto standard, hospital ICU-based CRRT equipment, either independently or together, for improved patient benefit.
Additionally, both devices will be deployed in hospital ICUs (pediatric and adult) by the same physicians for the same patients.